Cost-effectiveness analysis of rifaximin-α administration for the reduction of episodes of overt hepatic encephalopathy in recurrence compared with standard treatment in France.
about
Hepatic Encephalopathy: An Update on the Pathophysiology and Therapeutic Options.Economic impact of the use of rifaximin 550 mg twice daily for the treatment of overt hepatic encephalopathy in Italy.Recent advances in hepatic encephalopathy.Systematic Review of the Economic Burden of Overt Hepatic Encephalopathy and Pharmacoeconomic Impact of Rifaximin.
P2860
Cost-effectiveness analysis of rifaximin-α administration for the reduction of episodes of overt hepatic encephalopathy in recurrence compared with standard treatment in France.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Cost-effectiveness analysis of ...... standard treatment in France.
@en
Cost-effectiveness analysis of ...... standard treatment in France.
@nl
type
label
Cost-effectiveness analysis of ...... standard treatment in France.
@en
Cost-effectiveness analysis of ...... standard treatment in France.
@nl
prefLabel
Cost-effectiveness analysis of ...... standard treatment in France.
@en
Cost-effectiveness analysis of ...... standard treatment in France.
@nl
P2093
P2860
P356
P1476
Cost-effectiveness analysis of ...... h standard treatment in France
@en
P2093
Anastasiia Kabeshova
Elyonore Tsakeu
Robert Launois
Soumaia Ben Hariz
P2860
P304
P356
10.1177/1756283X16644249
P577
2016-05-01T00:00:00Z